Spruce Biosciences
NASDAQ: SPRB $57.93 USD
Late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders, with a lead program in classic congenital adrenal hyperplasia.
Company Info
Sector:Biopharmaceutical
Headquarters:South San Francisco, California, United States
Founded:2016
Website:sprucebio.com/
Upcoming Milestones & Key Dates
2026-Q4
Regulatory
NDA filing planned after successful FDA discussions
Clinical Development Pipeline
Crinecerfont
Target: CRF1 receptor antagonistRecent News
No recent news updates available for this company.